PhenomeX (Nasdaq:CELL) - Cotización, noticias y análisis

Resumen de acción CELL

PhenomeX Inc. operates as a functional cell biology company.

CELL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 23.43%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa ($100M)

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de PhenomeX Inc.

Champions Oncology

NasdaqCM:CSBR

US$65.9m

Alpha Teknova

NasdaqGM:TKNO

US$72.7m

Bioqual

OTCPK:BIOQ

US$64.8m

Harvard Bioscience

NasdaqGM:HBIO

US$165.9m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for PhenomeX
Historical stock prices
Current Share Price	US$1.00
52 Week High	US$3.65
52 Week Low	US$0.38
Beta	0.94
1 Month Change	2.90%
3 Month Change	116.98%
1 Year Change	-68.21%
3 Year Change	-98.85%
5 Year Change	n/a
Change since IPO	-98.48%

Noticias y actualizaciones recientes

Recent updates

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

May 16

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Apr 17

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Aug 15

Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development

Jun 09

Berkeley Lights Q1 2021 Earnings Preview

May 10

Rentabilidad de los accionistas

	CELL	US Life Sciences	Mercado US
7D	0.5%	-0.8%	-0.7%
1Y	-68.2%	1.0%	22.8%

Rentabilidad vs. Industria: CELL obtuvo unos resultados inferiores a los del sector US Life Sciences , que el año pasado arrojó un rendimiento del -6.7%.

Rentabilidad vs. Mercado: CELL obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.

Volatilidad de los precios

Is CELL's price volatile compared to industry and market?
CELL volatility
CELL Average Weekly Movement	40.4%
Life Sciences Industry Average Movement	6.9%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de CELL ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CELL ha aumentado de 23% a 40% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
n/a	285	Siddhartha Kadia	phenomex.com

Resumen de fundamentos de PhenomeX Inc.

¿Cómo se comparan los beneficios e ingresos de PhenomeX con su capitalización de mercado?
Estadísticas fundamentales de CELL
Capitalización bursátil	US$99.63m
Beneficios(TTM)	-US$124.53m
Ingresos (TTM)	US$71.82m

1.4x

Ratio precio-ventas (PS)

-0.8x

Ratio precio-beneficio (PE)

¿Está CELL sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CELL
Ingresos	US$71.82m
Coste de los ingresos	US$25.32m
Beneficio bruto	US$46.50m
Otros gastos	US$171.03m
Beneficios	-US$124.53m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.25
Margen bruto	64.75%
Margen de beneficio neto	-173.40%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CELL a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CELL

Recompensas

Análisis de riesgos

Competidores de PhenomeX Inc.

NasdaqCM:CSBR

US$65.9m

NasdaqGM:TKNO

US$72.7m

OTCPK:BIOQ

US$64.8m

NasdaqGM:HBIO

US$165.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Recent updates

Bruker Cellular Analysis, Inc. Files Form 15

Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform

PhenomeX Inc. Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark™ Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Consensus EPS estimates upgraded to US$1.13 loss

Consensus EPS estimates fall by 22%

Price target decreased by 29% to US$4.00

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

New major risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

PhenomeX Inc. to Report Q2, 2023 Results on Aug 14, 2023

PhenomeX Inc. Announces Lifting of the Stay in AbCellera Patent Infringement Case

PhenomeX Inc.(NasdaqGS:CELL) dropped from Russell Small Cap Comp Value Index

PhenomeX Receives a Notice from Nasdaq Regarding Minimum Bid Price Rule

PhenomeX Inc. Launches Beacon Quest™? Optofluidic System with Opto®? T Cell Profiling Workflows

Price target decreased by 31% to US$5.67

Consensus revenue estimates decrease by 16%, EPS upgraded

PhenomeX Inc. Launches Beacon Select Optofluidic System with Opto B Discovery Workflows

Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PhenomeX Inc. Provides Earning Guidance for the Full Year of 2023

PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity

Full year 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Berkeley Lights, Inc. Provides Preliminary Revenue Guidance for the Year Ended December 31, 2022

Berkeley Lights, Inc. (NasdaqGS:BLI) announced a definitive agreement to acquire IsoPlexis Corporation (NasdaqGS:ISO) from a group of shareholders for $56.3 million.

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Berkeley Lights Accelerating Antibody Discovery with Launch of Rabbit Memory B Cell Workflow

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Year 2022

Berkeley Lights, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Berkeley Lights, Inc. Announces Appointment of Scott Chaplin as Chief Legal Officer and Corporate Secretary

CEO & Director notifies of intention to sell stock

President of Global Operations notifies of intention to sell stock

Consensus revenue estimates fall by 17%

Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Berkeley Lights, Inc. Provides Revenue Guidance for the Full Year 2022

Berkeley Lights, Inc. and the Jaime Leandro Foundation Announce the Discovery, Functional Characterization, and Recovery of A Patient-Derived T Cell Receptor Sequence Against A Cancer Neoantigen

Berkeley Lights, Inc. Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

Berkeley Lights Inc. Announces Mehul Joshi as New Chief Financial Officer

Mehul Joshi joins Berkeley Lights as CFO

Berkeley Lights, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider notifies of intention to sell stock

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$16.80

High number of new directors

Berkeley Lights, Inc., Annual General Meeting, May 26, 2022

Berkeley Lights Announces Appointment of Lucas S. Vitale as Chief Human Resources Officer

Insider recently bought US$502k worth of stock

Berkeley Lights, Inc. Releases Upgrade to Its Software Suite for Beacon and Lightning Platforms

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Berkeley Lights, Inc. Reiterates Revenue Guidance for Full Year 2022

Price target decreased to US$30.40

Berkeley Lights, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Berkeley Lights, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case